Literature DB >> 35260844

Implementation of patient-reported outcome measures into health care for men with localized prostate cancer.

Udit Singhal1,2, Ted A Skolarus3,4, John L Gore5, Matthew G Parry6,7, Ronald C Chen8, Julie Nossiter7, Alan Paniagua-Cruz3, Arvin K George3, Paul Cathcart9, Jan van der Meulen6,7, Daniela A Wittmann3.   

Abstract

Measuring treatment-related quality of life (QOL) has become an increasingly requisite component of delivering high-quality care for patients with prostate cancer. Patient-reported outcome measures (PROMs) have, therefore, become an important tool for understanding the adverse effects of radical prostate cancer treatment and have been widely integrated into clinical practice. By providing real-time symptom monitoring and improved clinical feedback to patients and providers, PRO assessment has led to meaningful gains in prostate cancer care delivery and quality improvement worldwide. By providing an avenue for benchmarking, collaboration and population health monitoring, PROMs have delivered substantial improvements beyond providing individual symptom feedback. However, multilevel barriers exist that need to be addressed before the routine implementation of PROMs is achieved. Improvements in collection, interpretation, standardization and reporting will be crucial for the continued implementation of PROM instruments in prostate cancer pathways.
© 2022. Springer Nature Limited.

Entities:  

Mesh:

Year:  2022        PMID: 35260844     DOI: 10.1038/s41585-022-00575-4

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN: 1759-4812            Impact factor:   16.430


  98 in total

1.  Differences in urologist and patient assessments of health related quality of life in men with prostate cancer: results of the CaPSURE database.

Authors:  M S Litwin; D P Lubeck; J M Henning; P R Carroll
Journal:  J Urol       Date:  1998-06       Impact factor: 7.450

2.  Quality of life in prostatic carcinoma.

Authors:  F C da Silva
Journal:  Eur Urol       Date:  1993       Impact factor: 20.096

3.  Representation of elderly persons and women in published randomized trials of acute coronary syndromes.

Authors:  P Y Lee; K P Alexander; B G Hammill; S K Pasquali; E D Peterson
Journal:  JAMA       Date:  2001-08-08       Impact factor: 56.272

4.  Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer.

Authors:  J T Wei; R L Dunn; M S Litwin; H M Sandler; M G Sanda
Journal:  Urology       Date:  2000-12-20       Impact factor: 2.649

5.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.

Authors:  Hyuna Sung; Jacques Ferlay; Rebecca L Siegel; Mathieu Laversanne; Isabelle Soerjomataram; Ahmedin Jemal; Freddie Bray
Journal:  CA Cancer J Clin       Date:  2021-02-04       Impact factor: 508.702

6.  Perception of quality of life by patients, partners and treating physicians.

Authors:  K A Wilson; A J Dowling; M Abdolell; I F Tannock
Journal:  Qual Life Res       Date:  2000       Impact factor: 4.147

7.  How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30.

Authors:  Erik K Fromme; Kristine M Eilers; Motomi Mori; Yi-Ching Hsieh; Tomasz M Beer
Journal:  J Clin Oncol       Date:  2004-09-01       Impact factor: 44.544

8.  Differing perceptions of quality of life in patients with prostate cancer and their doctors.

Authors:  Geoffrey A Sonn; Natalia Sadetsky; Joseph C Presti; Mark S Litwin
Journal:  J Urol       Date:  2009-09-16       Impact factor: 7.450

9.  The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure.

Authors:  M S Litwin; R D Hays; A Fink; P A Ganz; B Leake; R H Brook
Journal:  Med Care       Date:  1998-07       Impact factor: 2.983

10.  Prospective assessment of the quality of life before, during and after image guided intensity modulated radiotherapy for prostate cancer.

Authors:  Joen Sveistrup; Ole Steen Mortensen; Jakob B Bjørner; Svend Aage Engelholm; Per Munck Af Rosenschöld; Peter Meidahl Petersen
Journal:  Radiat Oncol       Date:  2016-09-07       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.